Last reviewed · How we verify
Peg-P-IFN-alpha-2b (AOP2014)
Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity.
Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity. Used for Chronic hepatitis C, Chronic hepatitis B.
At a glance
| Generic name | Peg-P-IFN-alpha-2b (AOP2014) |
|---|---|
| Also known as | AOP2014, P1101 |
| Sponsor | AOP Orphan Pharmaceuticals AG |
| Drug class | Pegylated interferon alpha |
| Target | Interferon alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Virology / Immunology |
| Phase | Phase 3 |
Mechanism of action
This drug is a long-acting pegylated form of interferon alpha-2b, which binds to interferon alpha receptors on immune cells and hepatocytes to induce antiviral and immunomodulatory effects. The pegylation extends the drug's half-life, allowing for less frequent dosing. It is primarily used in viral hepatitis and certain malignancies where interferon-based immunotherapy is beneficial.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression / mood changes
- Injection site reactions
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- P1101 in Treating Patients With Myelofibrosis (PHASE2)
- AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (PHASE3)
- Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PHASE3)
- Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peg-P-IFN-alpha-2b (AOP2014) CI brief — competitive landscape report
- Peg-P-IFN-alpha-2b (AOP2014) updates RSS · CI watch RSS
- AOP Orphan Pharmaceuticals AG portfolio CI